Indivior (NASDAQ:INDV) Shares Gap Down to $17.05

Indivior PLC (NASDAQ:INDV) shares gapped down before the market opened on Wednesday . The stock had previously closed at $17.05, but opened at $16.60. Indivior shares last traded at $16.84, with a volume of 5,519 shares traded.

Analysts Set New Price Targets

Separately, Craig Hallum assumed coverage on Indivior in a report on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 price objective on the stock.

Indivior Stock Performance

The firm’s 50 day simple moving average is $19.19 and its 200 day simple moving average is $18.03. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of 1,672.00 and a beta of 0.63. The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.74 and a current ratio of 0.92.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, April 25th. The company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.01). Indivior had a net margin of 0.44% and a return on equity of 842.72%. The business had revenue of $284.00 million for the quarter, compared to analyst estimates of $300.00 million. Sell-side analysts forecast that Indivior PLC will post 2 earnings per share for the current fiscal year.

Institutional Trading of Indivior

A number of hedge funds have recently modified their holdings of INDV. Swiss National Bank boosted its position in Indivior by 1.0% in the 3rd quarter. Swiss National Bank now owns 287,897 shares of the company’s stock worth $6,257,000 after purchasing an additional 2,727 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in Indivior in the third quarter valued at $801,000. Liontrust Investment Partners LLP acquired a new position in shares of Indivior in the third quarter worth about $43,340,000. Deutsche Bank AG acquired a new position in shares of Indivior in the third quarter worth about $3,181,000. Finally, FMR LLC grew its position in shares of Indivior by 53.5% during the 3rd quarter. FMR LLC now owns 5,498,087 shares of the company’s stock valued at $119,339,000 after acquiring an additional 1,915,980 shares during the period. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.